title: Authors' reply to Lin and colleagues.
authors.affiliation: Johns Hopkins School of Medicine, Baltimore, MD, and Walter Reed National Military Medical Center, Bethesda, MD, USA scohen40@jhmi.edu.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Cohen
authors.affiliation: Penn State-Hershey Medical Center, Hershey, PA, USA.
authors.forename: Yakov
authors.initials: Y
authors.lastname: Vorobeychik
mesh_terms: D000588:Amines / Q000627:therapeutic use*; D000700:Analgesics / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D011843:Radiculopathy / Q000188:drug therapy*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
chemical_list: D000588:Amines; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D008775:Methylprednisolone